Literature DB >> 15163750

Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency.

Ke Lan1, Daniel A Kuppers, Subhash C Verma, Erle S Robertson.   

Abstract

Like other herpesviruses, Kaposi's sarcoma-associated herpesvirus (KSHV, also designated human herpesvirus 8) can establish a latent infection in the infected host. During latency a small number of genes are expressed. One of those genes encodes latency-associated nuclear antigen (LANA), which is constitutively expressed in cells during latent as well as lytic infection. LANA has previously been shown to be important for the establishment of latent episome maintenance through tethering of the viral genome to the host chromosomes. Under specific conditions, KSHV can undergo lytic replication, with the production of viral progeny. The immediate-early Rta, encoded by open reading frame 50 of KSHV, has been shown to play a critical role in switching from viral latent replication to lytic replication. Overexpression of Rta from a heterologous promoter is sufficient for driving KSHV lytic replication and the production of viral progeny. In the present study, we show that LANA down-modulates Rta's promoter activity in transient reporter assays, thus repressing Rta-mediated transactivation. This results in a decrease in the production of KSHV progeny virions. We also found that LANA interacts physically with Rta both in vivo and in vitro. Taken together, our results demonstrate that LANA can inhibit viral lytic replication by inhibiting expression as well as antagonizing the function of Rta. This suggests that LANA may play a critical role in maintaining latency by controlling the switch between viral latency and lytic replication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163750      PMCID: PMC416549          DOI: 10.1128/JVI.78.12.6585-6594.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  DNA binding by Kaposi's sarcoma-associated herpesvirus lytic switch protein is necessary for transcriptional activation of two viral delayed early promoters.

Authors:  D M Lukac; L Garibyan; J R Kirshner; D Palmeri; D Ganem
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus.

Authors:  C Boshoff; R A Weiss
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

3.  Kaposi's sarcoma-associated herpesvirus: a new human tumor virus, but how?

Authors:  T F Schulz; P S Moore
Journal:  Trends Microbiol       Date:  1999-05       Impact factor: 17.079

Review 4.  Molecular virology of Kaposi's sarcoma-associated herpesvirus.

Authors:  P S Moore; Y Chang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

5.  Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma.

Authors:  P Monini; S Colombini; M Stürzl; D Goletti; A Cafaro; C Sgadari; S Buttò; M Franco; P Leone; S Fais; P Leone; G Melucci-Vigo; C Chiozzini; F Carlini; G Ascherl; E Cornali; C Zietz; E Ramazzotti; F Ensoli; M Andreoni; P Pezzotti; G Rezza; R Yarchoan; R C Gallo; B Ensoli
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

6.  Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes.

Authors:  T Piolot; M Tramier; M Coppey; J C Nicolas; V Marechal
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus.

Authors:  A C Garber; M A Shu; J Hu; R Renne
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 8.  The role of HHV-8 in Kaposi's sarcoma.

Authors:  F Neipel; B Fleckenstein
Journal:  Semin Cancer Biol       Date:  1999-06       Impact factor: 15.707

9.  Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells.

Authors:  T S Hyun; C Subramanian; M A Cotter; R A Thomas; E S Robertson
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

10.  An Epstein-Barr virus isolated from a lymphoblastoid cell line has a 16-kilobase-pair deletion which includes gp350 and the Epstein-Barr virus nuclear antigen 3A.

Authors:  W Lee; Y H Hwang; S K Lee; C Subramanian; E S Robertson
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

View more
  125 in total

Review 1.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

2.  Tiled microarray identification of novel viral transcript structures and distinct transcriptional profiles during two modes of productive murine gammaherpesvirus 68 infection.

Authors:  Benson Yee Hin Cheng; Jizu Zhi; Alexis Santana; Sohail Khan; Eduardo Salinas; J Craig Forrest; Yueting Zheng; Shirin Jaggi; Janet Leatherwood; Laurie T Krug
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.

Authors:  Meir Shamay; Jianyong Liu; Renfeng Li; Gangling Liao; Li Shen; Melanie Greenway; Shaohui Hu; Jian Zhu; Zhi Xie; Richard F Ambinder; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Carboxyl-terminal amino acids 1052 to 1082 of the latency-associated nuclear antigen (LANA) interact with RBP-Jκ and are responsible for LANA-mediated RTA repression.

Authors:  Yi Jin; Zhiheng He; Deguang Liang; Quanzhi Zhang; Hongxing Zhang; Qiang Deng; Erle S Robertson; Ke Lan
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

5.  Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4/K10) is a novel interaction partner of CSL/CBF1, the major downstream effector of Notch signaling.

Authors:  Katharina Heinzelmann; Barbara A Scholz; Agnes Nowak; Even Fossum; Elisabeth Kremmer; Juergen Haas; Ronald Frank; Bettina Kempkes
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

6.  KSHV but not MHV-68 LANA induces a strong bend upon binding to terminal repeat viral DNA.

Authors:  Rajesh Ponnusamy; Maxim V Petoukhov; Bruno Correia; Tania F Custodio; Franceline Juillard; Min Tan; Marta Pires de Miranda; Maria A Carrondo; J Pedro Simas; Kenneth M Kaye; Dmitri I Svergun; Colin E McVey
Journal:  Nucleic Acids Res       Date:  2015-09-30       Impact factor: 16.971

7.  Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS.

Authors:  Guigen Zhang; Baca Chan; Naira Samarina; Bizunesh Abere; Magdalena Weidner-Glunde; Anna Buch; Andreas Pich; Melanie M Brinkmann; Thomas F Schulz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-25       Impact factor: 11.205

Review 8.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

9.  Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258.

Authors:  Qin Yan; Xinting Ma; Chenyou Shen; Xu Cao; Ninghan Feng; Di Qin; Yi Zeng; Jianzhong Zhu; Shou-Jiang Gao; Chun Lu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

10.  Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency.

Authors:  Qingmei Jia; Michael L Freeman; Eric J Yager; Ian McHardy; Leming Tong; DeeAnn Martinez-Guzman; Tammy Rickabaugh; Seungmin Hwang; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.